Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.

BACKGROUND

The recommended doxorubicin (DOX) dose for small dogs is 1 mg/kg. Recent data suggest that DOX-induced gastrointestinal (GI) toxicosis can be reduced with maropitant treatment.

OBJECTIVES

To investigate the incidence of adverse events (AEs) in small-breed dogs administered a single 25 mg/m DOX followed by administration of maropitant (DOX25). The primary aim was to assess myelo- and GI toxicoses for 2 weeks after DOX administration. The secondary aim was to compare the incidence and grades of AEs found in the DOX25 group with a historical control group (DOX 1 mg/kg without administration of antiemetic or antidiarrheal medications).

ANIMALS

Nineteen small-breed tumor-bearing dogs.

METHODS

A prospective, observational study of tumor-bearing dogs, weighing 5 to 10 kg, administered a single 25 mg/m dose of DOX IV, followed by administration of maropitant for the next 5 days.

RESULTS

Inappetence, vomiting, and diarrhea were found in 7/19, 2/19, and 6/19 of the DOX25 dogs, respectively. Neutropenia and thrombocytopenia was 12/19 and 3/19, respectively. Most AEs were grades 1 and 2, except for grades 3 and 4 inappetence and neutropenia in 3 and 4 dogs, respectively. Furthermore, febrile neutropenia occurred in 3/19 dogs in the DOX25 group. All AEs between the DOX25 and historical control groups were not significantly different.

CONCLUSIONS AND CLINICAL IMPORTANCE

Vomiting and diarrhea were deemed acceptable with 25 mg/m DOX followed by maropitant treatment in 5 to 10 kg dogs; however, additional supportive care might be needed for dogs with inappetence and neutropenia.